Abstract:Randomized clinical trials are often designed to assess whether a test treatment prolongs survival relative to a control treatment. Increased patient heterogeneity, while desirable for generalizability of results, can weaken the ability of common statistical approaches to detect treatment differences, potentially hampering the regulatory approval of safe and efficacious therapies. A novel solution to this problem is proposed. A list of baseline covariates that have the potential to be prognostic for survival under either treatment is pre-specified in the analysis plan. At the analysis stage, using all observed survival times but blinded to patient-level treatment assignment, 'noise' covariates are removed with elastic net Cox regression. The shortened covariate list is used by a conditional inference tree algorithm to segment the heterogeneous trial population into subpopulations of prognostically homogeneous patients (risk strata). After patient-level treatment unblinding, a treatment comparison is done within each formed risk stratum and stratum-level results are combined for overall statistical inference. The impressive power-boosting performance of our proposed 5-step stratified testing and amalgamation routine (5-STAR), relative to that of the logrank test and other common approaches that do not leverage inherently structured patient heterogeneity, is illustrated using a hypothetical and two real datasets along with simulation results. Furthermore, the importance of reporting stratum-level comparative treatment effects (time ratios from accelerated failure time model fits in conjunction with model averaging and, as needed, hazard ratios from Cox proportional hazard model fits) is highlighted as a potential enabler of personalized medicine. A fiveSTAR R package is available at <a class="link-external link-https" href="https://github.com/rmarceauwest/fiveSTAR" rel="external noopener nofollow">this https URL</a>.

Multiple random change points in survival analysis with applications to clinical trials

Bayesian analyses of multiple random change points in survival models with applications to clinical trials

Efficient estimation of Cox model with random change point

Multiple Change-Point Detection in Piecewise Exponential Hazard Regression Models with Long-Term Survivors and Right Censoring

Adjusting for time-varying treatment switches in randomized clinical trials: the danger of extrapolation and how to avoid it

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Teasing out the overall survival benefit with adjustment for treatment switching to other therapies

Survival Analysis in Clinical Trials: Past Developments and Future Directions

Leveraging machine learning: Covariate-adjusted Bayesian adaptive randomization and subgroup discovery in multi-arm survival trials

Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trial in Health Technology Assessment

Competing risks and multivariate outcomes in epidemiological and clinical trial research

Optimality of testing procedures for survival data

Statistical Considerations for Evaluating Treatment Effect under Various Non-proportional Hazard Scenarios

A flexible approach for causal inference with multiple treatments and clustered survival outcomes

Nonparametric analysis of delayed treatment effects using single‐crossing constraints

The multivariate Bernoulli detector: change point estimation in discrete survival analysis

Covariate-adjusted Group Sequential Comparisons of Survival Probabilities

Multivariate Rank-Based Analysis of Multiple Endpoints in Clinical Trials: A Global Test Approach

Weighted reverse counting process (WRCP): A novel approach to quantify the overall treatment effect with multiple time-to-event outcomes by adaptive weighting

Survival Analysis Using a 5-Step Stratified Testing and Amalgamation Routine in Randomized Clinical Trials

The design and analysis of randomized trials with recurrent events